Vitamin D3 Supplement Development: A Worked Example for a 50 mcg Softgel

About this worked example

This is a labelled worked example, not a client case study. The brand, product and every number in the results table are illustrative. Nothing on this page is a measured FRL result, and no client is quoted. The example shows how Food Research Lab would plan vitamin D3 supplement development for a US brand, using the US labelling and manufacturing rules^[1][2][3] and published stability research on vitamin D3.^[4][5]

The calculations use one stated assumption, 90% retention at 24 months, so the arithmetic can be followed. A real project replaces that assumption with stability data from the actual product in its actual pack.

The vitamin D3 supplement development brief

A US supplement brand wants a daily vitamin D3 softgel and has no stability data. It needs a formula, a specification and a stability plan under which every batch still meets its declared amount at the end of shelf life, with a compliant Supplement Facts panel.

Table 1. Worked-example brief

At 50 mcg the panel shows 250% of the 20 mcg Daily Value.^[2] One microgram of vitamin D equals 40 IU, so 50 mcg is 2,000 IU.^[6]

The challenge: a fragile vitamin with a floor on the label

Vitamin D3 degrades. A systematic study of vitamin D3 in aqueous media tested temperature, light, oxygen, pH and metal ions, and found metal ions and acidic conditions the most destabilising.^[4] A 2025 review of fortified foods lists ultraviolet light, air oxidation, heat, humidity and acid as the main threats, and reports over 90% of potency retained only with proper formulation, protective packaging and storage.^[5]

The label sets a floor. For a dietary supplement, FDA applies the Class I rule: an added nutrient must be at least the amount declared on the label, and reasonable excesses are acceptable within current good manufacturing practice.^[1][2] So the product has to start above 50 mcg, by enough to cover losses to expiry, without drifting towards the adult tolerable upper intake level of 100 mcg (4,000 IU) a day.^[6]

Formulation approach: softgel or tablet

The first decision is the dosage form. Vitamin D3 is fat-soluble, so a softgel can carry it dissolved in an oil fill, away from water. A tablet needs the vitamin in a powder form; published work shows directly compressed vitamin D3 tablets can meet pharmacopeial tests, with content between 98.77% and 102.35% of target and near-complete release at 90 minutes in one study.^[7] The brief asks for a softgel, so the screen focuses there.

Excipient screen

• Fill oil: chosen for oxidative stability, because oxygen degrades the vitamin.^[4][5]
• Antioxidant and chelator: in aqueous media, EDTA, ascorbic acid and citric acid each stabilised vitamin D3, with EDTA the strongest;^[4] an oil fill needs its own compatible antioxidant system, tested on the product.
• Shell and pack: opaque or light-protective shell and pack, because light drives photodegradation.^[5]

Our pillar guide to vitamin D overage in supplements explains how these choices feed the overage, and our guide to formulating a gummy supplement covers the same problem in a harder matrix.

Setting the overage: the arithmetic

The overage is sized from the expected loss to expiry: divide the label amount by the fraction expected to remain at expiry, then check the result against the upper level. The values below are calculated from the model’s single assumption, not measured.

Table 2. Overage calculation in this worked example (illustrative)

Two cautions apply. The upper level covers total daily intake from all sources, not just this product.^[6] And a real specification also needs room for assay and batch-to-batch variability, so the release limit is set from method validation data as well as the stability loss. For the same arithmetic under a different regulator, see our article on supplement label claims and overage in the UAE.

Testing and validation plan

Supplement stability testing runs in two tracks. Accelerated storage gives an early estimate of potency loss; real-time storage at the intended conditions confirms it. A supplement programme can use the storage conditions ICH Q1A(R2) sets for medicines as a reference, such as 25 °C/60% relative humidity long-term and 40 °C/75% relative humidity accelerated.^[8] Potency is measured with a validated stability-indicating assay, typically HPLC, as used in published vitamin D3 stability work.^[4] We run or arrange assay, dissolution and stability studies through accredited partner laboratories.

Dissolution comes before the first stability pull, so every time point is measured with the same validated method. USP general chapter <2040> sets disintegration and dissolution tests for dietary supplements.^[9] Our Inside the Lab article on vitamin D3 dissolution testing walks through the method. Underneath it all, 21 CFR Part 111 requires specifications for identity, purity, strength and composition, and verification that finished batches meet them.^[3]

Acceptance criteria

• Assay at release at or above the release target, within the specification limits.
• Assay at expiry at or above the declared 50 mcg in the weakest stability lot.^[1]
• Dissolution results within the limits of the validated method.^[9]
• Content uniformity within specification across the batch.
• Supplement Facts panel declares vitamin D in mcg, optional IU in parentheses and % Daily Value.^[1]

Our guide to real-time and accelerated shelf-life testing explains why accelerated data alone should not set a printed date.

Development plan and iterations

Each step changes one thing, so the effect of every decision is visible in the data.

1. Iteration 1: formulation screen. Two fill oils and two shell options, checked for appearance, assay and early accelerated loss.
2. Iteration 2: lock the fill. Fix the fill and antioxidant system; start the accelerated study on the chosen formula in the final pack.
3. Iteration 3: apply the overage. Set the release target from the loss seen so far, confirm release and dissolution, and start real-time storage.

If accelerated loss exceeds the plan, the pack or antioxidant system is revised before scale-up, not after. Our ashwagandha capsule worked example follows the same brief-to-specification logic for a botanical.

Scale-up and supply

Softgels are made on encapsulation lines at a contract manufacturer. FRL develops the formula, specification and stability plan, then transfers them to a manufacturing partner it introduces or to the brand’s own manufacturer, which must run the product under 21 CFR Part 111.^[3][10] The first commercial batches go on the same stability programme, because the pilot result has to be confirmed on the production process. Facility registration and other launch steps are covered in our guide to FDA food facility registration.

Lessons and key takeaways

• Size the overage from stability data, not habit; the model’s 90% retention is only a placeholder.^[4][5]
• Validate dissolution before the first stability pull, so every time point is comparable.^[9]
• Protect from light, oxygen and acid through fill, antioxidant, shell and pack choices.^[4][5]
• Check the release amount against the upper level as well as the label floor.^[6]
• Keep the panel, specification and claim in one document. Our FDA vitamin D supplement rules guide covers the label side.

For brands & formulators

If you are planning a vitamin D3 product for the US market, our nutraceutical product development team takes it from brief to a specification, overage and stability plan, with a Supplement Facts panel reviewed against 21 CFR 101.36. We run or arrange assay, dissolution and shelf-life studies through accredited partner laboratories.

Our regulatory and scientific research team reviews label wording and claims, and our nutraceutical manufacturing team connects you with manufacturing partners for commercial runs. Talk to a formulation expert.

In this series

• The VITAL trial explained: what the largest vitamin D trial found, including its null primary outcomes.
• FDA vitamin D supplement rules: Supplement Facts, mcg and IU, Daily Value, claims and cGMP.
• Vitamin D overage in supplements: the pillar guide to sizing an overage that holds the label claim.
• Vitamin D3 dissolution testing: an Inside the Lab walk-through of the release method.
• Vitamin D3 supplement development: a 50 mcg softgel worked example. You are here.
• Service: Nutraceutical product development at Food Research Lab.

1. U.S. Food and Drug Administration. (2026). 21 CFR 101.36: Nutrition labeling of dietary supplements. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/section-101.36 (cited for mcg declaration with optional IU in parentheses, % Daily Value, Class I compliance and reasonable excesses within cGMP).
2. U.S. Food and Drug Administration. (2026). 21 CFR 101.9: Nutrition labeling of food. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/section-101.9 (cited for the 20 mcg vitamin D RDI and the Class I rule in paragraph (g)(4)(i)).
3. U.S. Food and Drug Administration. (2026). 21 CFR Part 111: Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements (sections 111.70 and 111.75). Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/part-111 (cited for specifications and finished-batch verification).
4. Temova Rakuša, Ž., Pišlar, M., Kristl, A., & Roškar, R. (2021). Comprehensive stability study of vitamin D3 in aqueous solutions and liquid commercial products. Pharmaceutics, 13(5), 617. https://doi.org/10.3390/pharmaceutics13050617 (cited for degradation factors, stabilisers and stability-indicating HPLC).
5. Hardinsyah, H., Rahmawati, R., Sulaeman, A., & Nurkolis, F. (2025). A blueprint for vitamin D fortification in sugar: Stability and health impact. Frontiers in Nutrition, 12, 1671785. https://doi.org/10.3389/fnut.2025.1671785 (cited for light, oxygen, heat, humidity and acid as threats and over 90% retention with proper formulation, packaging and storage).
6. Institute of Medicine. (2011). Dietary reference intakes for calcium and vitamin D (A. C. Ross, C. L. Taylor, A. L. Yaktine, & H. B. Del Valle, Eds.), Chapter 6: Tolerable upper intake levels. National Academies Press. https://www.ncbi.nlm.nih.gov/books/n/nap13050/ch6/ (cited for the 4,000 IU (100 mcg) upper level and 1 mcg = 40 IU).
7. Haq, N., Ibrahim, M. A., Alsarra, I. A., Alshehri, S., Alam, P., & Shakeel, F. (2024). Utilization of waste eggshell powder as an excipient for vitamin D3 tablet preparation. ACS Omega, 9(3), 3980–3987. https://doi.org/10.1021/acsomega.3c08416 (cited for vitamin D3 tablets meeting pharmacopeial tests).
8. International Council for Harmonisation. (2003). Q1A(R2) Stability testing of new drug substances and products (FDA guidance for industry). U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products (cited for long-term and accelerated storage conditions used as a reference).
9. United States Pharmacopeia. (n.d.). <2040> Disintegration and dissolution of dietary supplements. USP–NF. https://doi.usp.org/USPNF/USPNF_M99970_04_01.html (cited for disintegration and dissolution tests for supplements).
10. Food Research Lab. (n.d.). Nutraceutical manufacturing: contract manufacturing of nutraceuticals and dietary supplements. https://www.foodresearchlab.com/what-we-do/pilot-contract-manufacturing/nutraceutical-manufacturing/ (cited for manufacturing through a partner network).